Russell I. Heigh
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Russell I. Heigh has a total of 82 co-authors. Here are the top co-authors by number of shared publications:
- David A. Ahlquist
Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota.
4 shared publications - Julie A. Simonson
Division of Gastroenterology and Hepatology, Mayo Clinic, 200 First Street SW, Rochester, MN, 55905, USA
4 shared publications - Mary E. Devens
Division of Gastroenterology, Mayo Clinic, Rochester, MN 55905, USA
3 shared publications - David E. Fleischer
Mayo Clinic Arizona
2 shared publications - Douglas W. Mahoney
Division of Biomedical Statistics and Informatics, Mayo Clinic, Rochester, Minnesota, USA
2 shared publications Fareeda T. Hussain
2 shared publications
Latest Publications
- 1 April 2016
- Published by Elsevier in Gastroenterology
- Vol. 150 (4) , S760
Mo1716 Long-Term Follow-Up of Patients Having False Positive Multi-Target Stool DNA Tests After Negative Screening Colonoscopy: The LONG-HAUL Study
- 1 April 2016
- Published by Elsevier in Gastroenterology
- Vol. 150 (4) , S760
Mo1716 Long-Term Follow-Up of Patients Having False Positive Multi-Target Stool DNA Tests After Negative Screening Colonoscopy: The LONG-HAUL Study
- Open Access
- 20 January 2014
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 9 (1) , e85659
Detection of Colorectal Serrated Polyps by Stool DNA Testing: Comparison with Fecal Immunochemical Testing for Occult Blood (FIT)
Precursors to 1/3 of colorectal cancer (CRC), serrated polyps have been under-detected by screening due to their inconspicuous, non-hemorrhagic, and proximal nature. A new multi-target stool DNA test (multi-target sDNA) shows high sensitivity for both CRC and advanced adenomas. Screen detection of serrated polyps by this approach requires further validation. We sought to assess and compare noninvasive detection of sessile serrated polyps (SSP) ≥1 cm by sDNA and an occult blood fecal immunochemical test (FIT). In a blinded prospective study, a single stool sample used for both tests was collected from 456 asymptomatic adults prior to screening or surveillance colonoscopy (criterion standard). All 29 patients with SSP≥1 cm were included as cases and all 232 with no neoplastic findings as controls. Buffered stool samples were processed and frozen on receipt; Exact Sciences performed sDNA in batches using optimized analytical methods. The sDNA multi-marker panel targets methylated BMP3 (mBMP3) and NDRG4, mutant KRAS, β-actin, and hemoglobin. FIT (Polymedco OC-FIT Check) was performed in separate lab ≤2 days post defecation and evaluated at cutoffs of 50 (FIT-50) and 100 ng/ml (FIT-100). Median ages: cases 61 (range 57–77), controls 62 (52–70), p = NS. Women comprised 59% and 51%, p = NS, respectively. SSP median size was 1.2 cm (1–3 cm), 93% were proximal, and 64% had synchronous diminutive polyps. Among multi-target sDNA markers, mBMP3 proved highly discriminant for detection of SSP≥1 cm (AUC = 0.87, pBMP3 was significantly greater than by FIT-50 (66% vs 10%, p = 0.0003) or FIT-100 (63% vs 0%, pBMP3. FIT appears to have no value in SSP detection.
- 20 January 2014
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 9 (1) , e85659
Open AccessDetection of Colorectal Serrated Polyps by Stool DNA Testing: Comparison with Fecal Immunochemical Testing for Occult Blood (FIT)
Precursors to 1/3 of colorectal cancer (CRC), serrated polyps have been under-detected by screening due to their inconspicuous, non-hemorrhagic, and proximal nature. A new multi-target stool DNA test (multi-target sDNA) shows high sensitivity for both CRC and advanced adenomas. Screen detection of serrated polyps by this approach requires further validation. We sought to assess and compare noninvasive detection of sessile serrated polyps (SSP) ≥1 cm by sDNA and an occult blood fecal immunochemical test (FIT). In a blinded prospective study, a single stool sample used for both tests was collected from 456 asymptomatic adults prior to screening or surveillance colonoscopy (criterion standard). All 29 patients with SSP≥1 cm were included as cases and all 232 with no neoplastic findings as controls. Buffered stool samples were processed and frozen on receipt; Exact Sciences performed sDNA in batches using optimized analytical methods. The sDNA multi-marker panel targets methylated BMP3 (mBMP3) and NDRG4, mutant KRAS, β-actin, and hemoglobin. FIT (Polymedco OC-FIT Check) was performed in separate lab ≤2 days post defecation and evaluated at cutoffs of 50 (FIT-50) and 100 ng/ml (FIT-100). Median ages: cases 61 (range 57–77), controls 62 (52–70), p = NS. Women comprised 59% and 51%, p = NS, respectively. SSP median size was 1.2 cm (1–3 cm), 93% were proximal, and 64% had synchronous diminutive polyps. Among multi-target sDNA markers, mBMP3 proved highly discriminant for detection of SSP≥1 cm (AUC = 0.87, pBMP3 was significantly greater than by FIT-50 (66% vs 10%, p = 0.0003) or FIT-100 (63% vs 0%, pBMP3. FIT appears to have no value in SSP detection.
- 1 May 2012
- Published by Elsevier in Gastroenterology
- Vol. 142 (5)
Tu1189 An Optimized Multi-Marker Stool Test for Colorectal Cancer Screening: Initial Clinical Appraisal
- 1 May 2012
- Published by Elsevier in Gastroenterology
- Vol. 142 (5)
Tu1189 An Optimized Multi-Marker Stool Test for Colorectal Cancer Screening: Initial Clinical Appraisal
- 31 May 2010
- Published by Elsevier in Gastroenterology
- Vol. 138 (5) , -352-352
M1195 Phase II Chemoprevention Trial of Atorvastatin (ATOR), Sulindac (Sul), Oligofructose-Enriched Inulin (Ofei), or Ofei Placebo (Ofeip) Among Subjects at Increased Risk for Sporadic Colorectal Cancer (CRC): A Cancer Prevention Network (CPN) Trial
- 31 May 2010
- Published by Elsevier in Gastroenterology
- Vol. 138 (5) , -352-352
M1195 Phase II Chemoprevention Trial of Atorvastatin (ATOR), Sulindac (Sul), Oligofructose-Enriched Inulin (Ofei), or Ofei Placebo (Ofeip) Among Subjects at Increased Risk for Sporadic Colorectal Cancer (CRC): A Cancer Prevention Network (CPN) Trial
- Open Access
- 1 January 2010
- Published by S. Karger AG in Case Reports in Gastroenterology
- Vol. 4 (1) , 35-40
Coexisting Crohn’s Disease and Takayasu’s Arteritis in Two Patients Treated with Anti-TNF-α Therapies
Crohn’s disease (CD) and Takayasu’s arteritis (TA) are inflammatory granulomatous autoimmune disorders. Simultaneous occurrence of CD and TA in the same individual is rare. We report two cases treated with biologic agents. Case 1: A 16-year-old male presented with abdominal pain, nausea, vomiting. CT angiogram showed thickening of the terminal ileum, wall thickening and narrowing of multiple large and medium arteries including aorta and left common carotid. Colonoscopy with biopsy of the stenotic ileocecal valve confirmed CD. Resected carotid artery pathology was consistent with TA. Treatment was initially begun with prednisone, then methotrexate was started followed by infliximab. Due to side effects, methotrexate was switched to azathioprine. He remained asymptomatic. Case 2: A 38-year-old male with well-characterized Crohn’s ileocolitis for 15 years, who had been treated with prednisone, mesalamine, sulfasalazine, and azathioprine presented with chest, upper back and abdominal pain. CT angiogram showed vasculitis of large and medium arteries, with stenosis of the right renal artery, and wall thickening of the sigmoid colon. He was diagnosed with TA. He underwent treatment with infliximab and adalumimab on different occasions, which were later discontinued due to fever, bacteremia and complications from sepsis. He remained on prednisone and azathioprine. In these two patients with both CD and TA the diagnoses were confirmed by imaging and pathologic findings. Both patients developed vascular complications. Tumor necrosis factor inhibitor therapy was effective in one patient but discontinued in the other due to infection. Further research into the association of CD and TA may provide clues to their etiologies and guide effective interventions.
- 1 January 2010
- Published by S. Karger AG in Case Reports in Gastroenterology
- Vol. 4 (1) , 35-40
Open AccessCoexisting Crohn’s Disease and Takayasu’s Arteritis in Two Patients Treated with Anti-TNF-α Therapies
Crohn’s disease (CD) and Takayasu’s arteritis (TA) are inflammatory granulomatous autoimmune disorders. Simultaneous occurrence of CD and TA in the same individual is rare. We report two cases treated with biologic agents. Case 1: A 16-year-old male presented with abdominal pain, nausea, vomiting. CT angiogram showed thickening of the terminal ileum, wall thickening and narrowing of multiple large and medium arteries including aorta and left common carotid. Colonoscopy with biopsy of the stenotic ileocecal valve confirmed CD. Resected carotid artery pathology was consistent with TA. Treatment was initially begun with prednisone, then methotrexate was started followed by infliximab. Due to side effects, methotrexate was switched to azathioprine. He remained asymptomatic. Case 2: A 38-year-old male with well-characterized Crohn’s ileocolitis for 15 years, who had been treated with prednisone, mesalamine, sulfasalazine, and azathioprine presented with chest, upper back and abdominal pain. CT angiogram showed vasculitis of large and medium arteries, with stenosis of the right renal artery, and wall thickening of the sigmoid colon. He was diagnosed with TA. He underwent treatment with infliximab and adalumimab on different occasions, which were later discontinued due to fever, bacteremia and complications from sepsis. He remained on prednisone and azathioprine. In these two patients with both CD and TA the diagnoses were confirmed by imaging and pathologic findings. Both patients developed vascular complications. Tumor necrosis factor inhibitor therapy was effective in one patient but discontinued in the other due to infection. Further research into the association of CD and TA may provide clues to their etiologies and guide effective interventions.
- 31 May 2009
- Published by Elsevier in Gastroenterology
- Vol. 136 (5) , A-625-625
T2036 Pan-Detection of Gastrointestinal Neoplasms By Stool DNA Testing: Establishment of Feasibility
- 31 May 2009
- Published by Elsevier in Gastroenterology
- Vol. 136 (5) , A-625-625
T2036 Pan-Detection of Gastrointestinal Neoplasms By Stool DNA Testing: Establishment of Feasibility
- 31 May 2009
- Published by Elsevier in Gastroenterology
- Vol. 136 (5) , A-115-115
751c Effectiveness of the Third Eye Retroscope for Detecting Polyps in the Right Colon
- 31 May 2009
- Published by Elsevier in Gastroenterology
- Vol. 136 (5) , A-115-115
751c Effectiveness of the Third Eye Retroscope for Detecting Polyps in the Right Colon
- 31 May 2009
- Published by Elsevier in Gastroenterology
- Vol. 136 (5)
T2034 Stool DNA and Occult Blood for Detection of Colorectal Cancer: Complementary Markers
- 31 May 2009
- Published by Elsevier in Gastroenterology
- Vol. 136 (5)
T2034 Stool DNA and Occult Blood for Detection of Colorectal Cancer: Complementary Markers
- Open Access
- 9 April 2009
- Published by Springer Nature in BMC Gastroenterology
- Vol. 9 (1) , 24-7
Use of an electromagnetic colonoscope to assess maneuvers associated with cecal intubation
- 9 April 2009
- Published by Springer Nature in BMC Gastroenterology
- Vol. 9 (1) , 24-7
Open AccessUse of an electromagnetic colonoscope to assess maneuvers associated with cecal intubation
- Open Access
- 8 June 2007
- Published by Springer Nature in BMC Gastroenterology
- Vol. 7 (1) , 1-5
Comparison of morning versus afternoon cecal intubation rates
Background: Many factors impacting cecal intubation rates have been examined in detail; however, little information exists regarding the effect of the timing of the procedure. We sought to examine any difference in cecal intubation rates between morning and afternoon colonoscopies and identify factors contributing to a discrepancy. Methods: Retrospective, single-center study comparing cecal intubation rates for colonoscopies performed in the morning (begun prior to 12 noon) and colonoscopies performed in the afternoon (begun after 12 noon) over an approximately 12 month period. Univariate and multivariate analyses were performed evaluating patient demographics, procedure indication(s), endoscopist, bowel preparation type and quality, and participation by a gastroenterology fellow. Results: 6087 colonoscopies were evaluated in this study. Colonoscopies (n = 3729) performed in the morning were compared to colonoscopies performed in the afternoon (n = 2358). The crude completion rate to the cecum was 95.0% in the morning group while the completion rate to the cecum was 93.6% of the afternoon exams (p = 0.02). The morning colonoscopies had better bowel preparation quality (p < 0.001). The multivariate analyses demonstrated that gender, age, and bowel preparation quality impacted completion rates. After correcting for these factors, there was no significant difference in completion rates in the morning versus afternoon. Conclusion: Uncorrected cecal intubation rates were lower in the afternoon compared to the morning in outpatients undergoing colonoscopy. Bowel preparation quality was worse in the afternoon compared with the morning. Efforts at improving afternoon bowel preparation may improve the outcome of afternoon colonoscopies.
- 8 June 2007
- Published by Springer Nature in BMC Gastroenterology
- Vol. 7 (1) , 1-5
Open AccessComparison of morning versus afternoon cecal intubation rates
Background: Many factors impacting cecal intubation rates have been examined in detail; however, little information exists regarding the effect of the timing of the procedure. We sought to examine any difference in cecal intubation rates between morning and afternoon colonoscopies and identify factors contributing to a discrepancy. Methods: Retrospective, single-center study comparing cecal intubation rates for colonoscopies performed in the morning (begun prior to 12 noon) and colonoscopies performed in the afternoon (begun after 12 noon) over an approximately 12 month period. Univariate and multivariate analyses were performed evaluating patient demographics, procedure indication(s), endoscopist, bowel preparation type and quality, and participation by a gastroenterology fellow. Results: 6087 colonoscopies were evaluated in this study. Colonoscopies (n = 3729) performed in the morning were compared to colonoscopies performed in the afternoon (n = 2358). The crude completion rate to the cecum was 95.0% in the morning group while the completion rate to the cecum was 93.6% of the afternoon exams (p = 0.02). The morning colonoscopies had better bowel preparation quality (p < 0.001). The multivariate analyses demonstrated that gender, age, and bowel preparation quality impacted completion rates. After correcting for these factors, there was no significant difference in completion rates in the morning versus afternoon. Conclusion: Uncorrected cecal intubation rates were lower in the afternoon compared to the morning in outpatients undergoing colonoscopy. Bowel preparation quality was worse in the afternoon compared with the morning. Efforts at improving afternoon bowel preparation may improve the outcome of afternoon colonoscopies.